Use of Methazolamide to Lower Intraocular Pressure

• Status: Not yet recruiting
• Trial end date: 2023-08-07
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: Methazolamide

Criteria

Inclusion Criteria:

• Males and females between 50 and 90 years old

• Current diagnosis of open angle glaucoma (OAG) in both eyes

• Subjects with untreated IOP between 18mmHg - 35mmHg (following washout of current IOP lowering medications if needed).

• Ability to be washed out of medications safely per the judgement of the treating physician.

• Ability to read and write in English

Exclusion Criteria:

• Glaucoma other than OAG

• Severe or end-stage glaucoma (cup to disc ratio >0.8 or Mean Deviation on Visual Field worse than -12)

• History of active, severe, unstable, or uncontrolled renal or hepatic dysfunction

• History of adrenocortical insufficiency

• History of electrolyte imbalance state such as hyperchloremic acidosis or sodium and potassium depletion states

• History of intolerance to study medications

• History of allergies to sulfa medications

• History of diabetes mellitus

• Currently on topical or systemic steroid therapy

• Currently or history of receiving intraocular injections

• Less than 30 days stable dosing regimen prior to visit 1 of any medications (excluding topical IOP-lowering treatments) or substances used on a chronic basis that may affect IOP. If use greater than 30 days, medications should not be changed during study

• Pregnant or breast-feeding women